IWY 357
Alternative Names: IWY-357Latest Information Update: 08 Oct 2025
At a glance
- Originator Medicines for Malaria Venture; Novartis
- Class Antimalarials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Malaria
Most Recent Events
- 30 Jul 2025 Preclinical trials in Malaria (Prevention) in Switzerland (Parenteral) before July 2025 (Medicine for Malaria Venture pipeline, July 2025)
- 30 Jul 2025 Pharmacodynamics data from a preclinical studies in Malaria released by Medicines for Malaria Venture (Medicines for Malaria Venture pipeline, July 2025)
- 30 Jul 2025 Medicine for Malaria Venture plans a clinical trial for Malaria (Medicine for Malaria Venture pipeline, July 2025)